The company's Advanced Therapy Access Program, which began in 2007, offers individually tailored oncolytic virus therapy to cancer patients who have failed standard-of-care treatments. Based on extensive scientific research at the University of Helsinki, the program has already treated 200 patients with strong safety and efficacy results. Oncos Therapeutics also develops CGTG-102, an oncolytic adenovirus that stimulates anti-tumor immune responses.